Multiple biomarkers measurement to estimate the duration of atrial fibrillation.

Autor: Arbault-Biton C; Cardiology Department, Avicenne University Hospital, APHP, Université Sorbonne Paris Nord, Bobigny, France., Chenevier-Gobeaux C; Department of Automated Biological Diagnostic, Cochin University Hospital, APHP.Centre-Université Paris, Paris, France., Legallois D; Cardiology Department, Caen University Hospital, Caen, France., Msadek S; Cardiology Department, Avicenne University Hospital, APHP, Université Sorbonne Paris Nord, Bobigny, France., Boubaya M; Department of Clinical Research, Avicenne University Hospital, APHP, Bobigny, France., Roule V; Cardiology Department, Caen University Hospital, Caen, France., Boukertouta T; Cardiology Department, Avicenne University Hospital, APHP, Université Sorbonne Paris Nord, Bobigny, France., Goudot FX; Cardiology Department, Avicenne University Hospital, APHP, Université Sorbonne Paris Nord, Bobigny, France., Beygui F; Cardiology Department, Caen University Hospital, Caen, France., Meune C; Cardiology Department, Avicenne University Hospital, APHP, Université Sorbonne Paris Nord, Bobigny, France.
Jazyk: angličtina
Zdroj: Annals of clinical biochemistry [Ann Clin Biochem] 2021 Mar; Vol. 58 (2), pp. 102-107. Date of Electronic Publication: 2020 Nov 27.
DOI: 10.1177/0004563220975171
Abstrakt: Background: An accurate estimation of the duration of atrial fibrillation is critical for its safe management. Recent studies suggested that copeptin, carbohydrate antigen-125, galectin-3 and growth differentiation factor-15 are increased in atrial fibrillation. We examined the ability of these markers to identify patients presenting with atrial fibrillation of ≤48 versus >48 h duration.
Methods: Retrospective analysis of a prospective study that included patients with atrial fibrillation of known duration.
Results: A total of 98 patients were analysed, 47 with atrial fibrillation ≤48 h and 51 with >48 h. In patients presenting with atrial fibrillation of ≤48 versus >48 h duration, the mean carbohydrate antigen-125 concentration was 16.9 ± 12.5 versus 30.9 ± 36.3 U/mL ( P  = 0.01), and growth differentiation factor-15 concentration was 1320 ± 889 versus 2608 ±2163 pg/mL ( P  < 0.001). Copeptin concentration was not independently associated with atrial fibrillation duration. The galectin-3 concentration did not differ between groups. Area under the ROC curve to identify patients with atrial fibrillation ≤48 h was 0.869 for carbohydrate antigen-125, 0.853 for growth differentiation factor-15.
Conclusion: The plasma concentrations of carbohydrate antigen-125, growth differentiation factor-15 and copeptin, but not galectin-3, are higher in patients presenting with atrial fibrillation of >48 h duration than in those with atrial fibrillation ≤48 h. The ability to discriminate recent atrial fibrillation offered by carbohydrate antigen-125 and growth differentiation factor-15 seems high.
Databáze: MEDLINE
Externí odkaz: